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The Challenge of Estimating Disability due to
Schistosomiasis
Schistosoma parasites are disease-producing trematodes, or ‘‘blood
flukes’’, that infect an estimated 207 million people worldwide [1].
Although schistosomes are common in the developing world, their
role in human disease and disability is not widely appreciated, even
by tropical medicine and health policy specialists [2]. A disability
analysis reported by Finkelstein and colleagues inthis edition of PLoS
Neglected Tropical Diseases [3] is part of a new research movement that
aims to correct this problem.
By way of background, it should be recognized that any infection
withthemajorspeciesthataffecthumans,i.e.,Schistosomahaematobium,
S. mansoni,o rS. japonicum, can cause chronic disability [4].
Schistosome transmission occurs in or near freshwater, and requires
the presenceof specificintermediate hostsnails[5]. Schistosomiasis is
also strongly associated with poverty—snail-bearing water must be
contaminated by human sewage for the snails to acquire their
infection. Then, in turn, people must come into contact with the
same snail-infested areas in order to become infected. In less-
developed communities that have only limited water resources,
exposure to infection is often unavoidable. As a rule, over a person’s
lifetime, schistosome infection will happen in recurrent waves
throughout childhood and adulthood. Where snails prevail and
there are no options for safe water, schistosomiasis is a common fact
of life [6]. Once human infection is established, schistosomiasis can
last for years. It results in chronic immune-mediated inflammation
induced by parasite eggs that are trapped in host tissues. The
consequence is decades of active tissue damage leading to tissue
fibrosis, organ damage, and, potentially, to severeillness or death [7].
How debilitating is it for an average person to have
schistosomiasis? This is an important question, and one that has
not been well answered in the past. It is particularly relevant that
we have an accurate disability estimate because in the Global
Burden of Disease (GBD) program’s disability-adjusted life year
(DALY) ranking system [8], it is the average health impact of
schistosomiasis that determines the clinical and public health
commitment to treat or prevent schistosome infection.
In past decades, the day-to-day impact of schistosomiasis was
often minimized as ‘‘asymptomatic’’, except when certain schisto-
somiasis-specific pathologies such as advanced hepatosplenomegaly,
intestinal bleeding (in the case of S. mansoni and S. japonicum)o r
bladder cancer, hydronephrosis, or renal failure (S. haematobium)
occurred [9]. Past researchers’ focus on these relatively rare clinical
outcomes led policymakers of the 1980s and 1990s to conclude that,
on average, schistosomiasis was not much of a public health problem
[10,11]. Those who have carefully re-examined the GBD program’s
DALY rankings [10] believe that the 0.5%–0.6% disability weight
assigned to schistosomiasis must reflect this ‘‘minimal average
impact’’ viewpoint. In addition, because of difficulties in attributing
certain syndromic outcomes to specific infections, in the GBD
weighting assessments, outcomes such as anemia, advanced liver
disease, and epilepsy were disaggregated away from schistosomiasis,
to be included as separate ‘‘diagnoses’’, in a process that numerically
devalued the importance of preventing schistosome infection.
Accordingly, in health policymaking, schistosomiasis was relegated
to be one of the most ‘‘neglected’’ among the neglected tropical
diseases (NTDs) [4,12].
In reality, the day-to-day experience of schistosomiasis involves
a number of under-acknowledged, insidious, sub-clinical morbid-
ities that affect patients on a daily basis. Many current studies are
now focusing on these aspects of disease, including performance-
related impacts such as chronic anemia, malnutrition, cognitive
impairment, and physical endurance. However, to dispute the
GBD program’s previous underassessments, we need further,
evidence-based assessments that will provide more valid overall
disability weights that can be used to add up the lifetime health
burden of having an ‘‘average’’ infection with schistosomiasis [4].
A New Study
Finkelstein and colleagues [3], in their current re-estimation of
schistosomiasis-related disability, have used a new approach to
reevaluate and recapture this burden of disease. Their study
focused on S. japonicum infection, the Asian/Philippine form of
schistosomiasis [13]. Their analytic approach utilized a decision
tree model to assess disease impact separately for children and
adults. The model parameters were populated using prevalence
data taken from the existing literature, and the resulting trees were
used to calculate the expected aggregate burden of disease for the
average adult or child who is currently infected with S. japonicum.
For known schistosomiasis complications such as diarrhea,
anemia, epilepsy, and cognitive impairment, which had been
previously disaggregated from schistosomiasis in the GBD system,
the needed disability weight estimates were taken directly from the
GBD program’s own DALY system. The decision model approach,
based on conditional probabilities of having or advancing to
particular schistosomiasis-associated health state, will be familiar to
those who use Markov health state modeling. The study’s tree-based
analysis involved stepwise reconstruction of the variable life paths
possible during and after S. japonicum infection [3]. Their results
indicate a significantly higher aggregate disability impact of 9.8%
disability for children and 18.6% disability for adults having
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to the 0.5%–0.6% disability weight assigned for every schistosome
species by the GBD program’s original DALY rankings [10]. Of
special note, these new S. japonicum disability estimates conform
closely to estimates derived for chronic schistosomiasis japonica in
China that were recently obtained by Jia and colleagues [14] using a
very different quality of life (QoL) patient questionnaire approach.
This evident consensus provides us confidence that these new
estimates are indeed more appropriate measures of schistosomiasis-
associated disability than those utilized in the GBD study.
Strengths and Limitations of the New Study
The main strength of this new study is that it provides a
systematic, evidence-based approach toward assessment of mor-
bidity and disability in schistosomiasis. Its strong concordance with
recent QoL/QALY assessments [14] suggests that its valuation of
disease impact is more realistic than that derived from the GBD’s
person trade-off (PTO) exercise, which was derived from scenario-
based judgments of non-expert panels [10].
Kirigia [15], in doing ‘‘expected quality-of-life’’ assessments in
Kenya, has highlighted the fact that anyone’s valuation of a disease’s
importance depends strongly on his or her perception of the
likelihood that the disease will progress to advanced disability or
death. Thanks to the present study, we now have firm summary
evidence on which to base such predictions. In retrospect, it seems
likely that the original GBD program’s panels were not given
scenarios that reflected the true risk of schistosomiasis-related disease
formation. This was particularly evident for S. japonicum,w h i c hi n
many respects causes more inflammation than is seen with the other
schistosome species,S.mansoni and S.haematobium[13],based,inpart,
on its significantly higher rate of egg production [16]. Thus, the
present study provides more useful, species-specific evidence for
disease burden in the S. japonicum–affected countries of the world.
Kirigia also cautions that simply going to experts (the ‘‘delphi’’
method) is not the solution to obtain probabilistic data for life-path
analysis, ‘‘. . . mainly because [experts] often do not think in the
ways required by economic evaluation . . .’’ [2]. Until recently
[17,18,19], our lack of longitudinal studies providing data on
morbidity incidence and on the long-term outcomes of treatment has
made it difficult to construct an informed, evidence-based scenario
of disease outcomes in schistosomiasis. The Finkelstein et al. paper
now helps to resolve this issue.
In terms of limitations, it must be noted that the current analysis is
restricted only to S. japonicum–related disease outcomes. The authors
also note that there were some significant gaps in the available data
for certain infection-related outcomes, and these, therefore, could
not be included. Variation of the outcomes by location and by
treatment status also could not be provided, pointing the way to
areas where future researchcan be done. In addition, the problem of
fairly redistributing the currently aggregated DALY values for
anemia, malnutrition, etc., needs to be further assessed for multiple
infections [20], and the interaction effects between schistosomiasis
and other diseases needs to be further defined so that we can better
estimate the benefits to be gained from combined NTD treatment
and control programs [21].
Implications for Schistosomiasis Research and
Control
This paper’s message should urgently reach the directors of the
GBD initiative. This program, now headquartered at the
University of Washington, is presently undertaking an extensive
revision of the 1996 GBD report [22] in a program called GBD
2005. It is evident that GBD 2005 should not just concentrate on
reevaluating patient numbers, but should also reassess all disability
weight assignments for non-lethal chronic diseases, including
NTDs in developing countries. The needed re-evaluation of
morbidity due to polyparasitism and the NTD link to environ-
mental issues is further discussed in a recent Viewpoint article by
Singer and Ryff in PLoS Neglected Tropical Diseases [23]. It is also
evident that whenever NTDs cause late complications, for
purposes of DALY computations the duration of these NTD
should be considered to last well beyond the period of patent
infection. Now that we have a variety of evidence-based
approaches indicating that schistosomiasis disability impact has a
credible range from 2%–25%, [3,4,14], it is important that the
DALY disability weighting system reflect this reality.
Critics have argued that if we take the same approach for all
diseases, it would result in similar increases in disability weights and
in DALY scores for all the NTDs, with no significant change in their
rankings among the global disease ‘‘league tables’’ [24]. However, if
health decisions are being based on ‘‘cost per DALY averted’’ [25],
then it is critical to have numerically accurate DALY valuations. It is
only in this fashion that the real benefits of controlling NTDs will be
appreciated [25]. Because several of the NTDs can be treated
together, then multi-drug deworming interventions can also be
viewed as a ‘‘market basket’’ of potentially synergistic benefits. The
NTD basket certainly ranks at the top of the list for all diseases in the
developing world [26], and ranks among he most prevalent of all
communicable and non-communicable diseases globally [21,27].
Ultimately, the new measures of schistosomiasis-associated disability
will translate into a greater priority to control schistosomiasis.
Incorporation of such new approaches and findings to GBD 2005
will be essential to providing a balanced and fair assessment of
NTDs, and for properly setting disease control priorities for these
disabling diseases of poverty [20,28].
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